Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RMD Stock Forecast 2025-2026
$245.78
Current Price
$35.78B
Market Cap
Buy 12
Hold 6
Sell 1
Wall St Analyst Ratings
Distance to RMD Price Targets
+20.0%
To High Target of $295.00
+11.5%
To Median Target of $274.00
-18.6%
To Low Target of $200.00
RMD Price Momentum
-1.1%
1 Week Change
+14.8%
1 Month Change
+12.6%
1 Year Change
+7.5%
Year-to-Date Change
-6.6%
From 52W High of $263.05
+37.0%
From 52W Low of $179.42
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching ResMed (RMD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RMD and similar high-potential opportunities.
Latest RMD Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, RMD has a bullish consensus with a median price target of $274.00 (ranging from $200.00 to $295.00). The overall analyst rating is Buy (7.9/10). Currently trading at $245.78, the median forecast implies a 11.5% upside. This outlook is supported by 12 Buy, 6 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Craig Wong-Pan at RBC Capital, suggesting a 18.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RMD Analyst Ratings
12
Buy
6
Hold
1
Sell
RMD Price Target Range
Low
$200.00
Average
$274.00
High
$295.00
Current: $245.78
Latest RMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 24, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $248.00 |
| Apr 24, 2025 | JP Morgan | David Low | Overweight | Maintains | $290.00 |
| Apr 24, 2025 | UBS | Laura Sutcliffe | Buy | Maintains | $285.00 |
| Apr 24, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $274.00 |
| Apr 24, 2025 | RBC Capital | Craig Wong-Pan | Sector Perform | Maintains | $255.00 |
| Apr 21, 2025 | Keybanc | Tim Rezvan | Overweight | Maintains | $269.00 |
| Mar 5, 2025 | Stifel | Jonathan Block | Hold | Maintains | $240.00 |
| Mar 5, 2025 | Citigroup | Mathieu Chevrier | Buy | Upgrade | $0.00 |
| Jan 31, 2025 | JP Morgan | David Low | Overweight | Maintains | $286.00 |
| Jan 31, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $260.00 |
| Jan 31, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Jan 31, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $280.00 |
| Jan 10, 2025 | Piper Sandler | Adam Maeder | Neutral | Initiates | $252.00 |
| Dec 13, 2024 | Stifel | Jonathan Block | Hold | Initiates | $250.00 |
| Oct 25, 2024 | RBC Capital | Craig Wong-Pan | Sector Perform | Maintains | $232.00 |
| Oct 25, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $266.00 |
| Oct 25, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 25, 2024 | Baird | Joe Vruwink | Outperform | Maintains | $283.00 |
| Oct 1, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 1, 2024 | RBC Capital | Craig Wong-Pan | Sector Perform | Maintains | $224.00 |
ResMed Inc. (RMD) Competitors
The following stocks are similar to ResMed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ResMed Inc. (RMD) Financial Data
ResMed Inc. has a market capitalization of $35.78B with a P/E ratio of 27.4x. The company generates $5.02B in trailing twelve-month revenue with a 26.2% profit margin.
Revenue growth is +7.9% quarter-over-quarter, while maintaining an operating margin of +33.0% and return on equity of +25.8%.
Valuation Metrics
Market Cap
$35.78B
Enterprise Value
$35.93B
P/E Ratio
27.4x
PEG Ratio
23.7x
Price/Sales
7.1x
Growth & Margins
Revenue Growth (YoY)
+7.9%
Gross Margin
+59.3%
Operating Margin
+33.0%
Net Margin
+26.2%
EPS Growth
+21.5%
Financial Health
Cash/Price Ratio
+2.6%
Current Ratio
3.4x
Debt/Equity
15.1x
ROE
+25.8%
ROA
+14.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
ResMed Inc. (RMD) Business Model
About ResMed Inc.
What They Do
Develops devices for sleep and respiratory health.
Business Model
ResMed generates revenue by manufacturing and selling advanced medical devices for sleep apnea, COPD, and respiratory conditions. Their product line includes CPAP devices, bilevel systems, and ventilators, all designed to improve patient comfort. Additionally, the company leverages cloud-connected technology to offer monitoring and telemedicine services, enhancing patient engagement and compliance.
Additional Information
ResMed operates on a global scale, focusing on both personal health and broader healthcare solutions. Their innovative approach positions them as a leader in the medical device sector, addressing the increasing demand for effective treatments related to sleep and respiratory health.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
9,980
CEO
Mr. Michael J. Farrell BE, MBA, SM
Country
United States
IPO Year
1995
Website
www.resmed.comResMed Inc. (RMD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
May 19, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Zacks Style Scores help investors identify top-rated stocks aligned with their investing styles, providing a useful tool for stock selection.
Why It Matters
The Zacks Style Scores help identify high-potential stocks tailored to specific investing strategies, enhancing decision-making and potentially increasing returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investing in strong growth stocks and holding them long-term can significantly build wealth and prepare for a comfortable retirement.
Why It Matters
Strong growth stocks can significantly enhance long-term wealth accumulation, crucial for retirement planning, indicating potential investment opportunities for future financial security.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Resmed (NYSE: RMD, ASX: RMD) has become the Official Sleep Partner for the Qatar Airways British & Irish Lions Tour to Australia, enhancing its brand visibility in the sports sector.
Why It Matters
Resmed's partnership with a major sports event enhances brand visibility and market reach, potentially driving sales growth and investor confidence in the company’s future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Resmed Acquires VirtuOx
21 days ago
Quick Summary
Resmed's recent acquisition boosts its virtual care growth, increases diagnostic access, and improves the digital experience for both patients and providers.
Why It Matters
Resmed's acquisition boosts its position in virtual care, potentially increasing revenue and market share, while improving patient and provider engagement. This could enhance investor confidence and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zacks Premium research service offers Zacks Style Scores, which assist investors—regardless of their strategy—in identifying strong stocks.
Why It Matters
The Zacks Style Scores enhance stock selection, potentially leading to better investment decisions and improved returns across various investing strategies.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The Top 15 High-Growth Dividend stocks for April 2025 gained 0.12%, outperforming SPY and VIG. Year-to-date, they returned -0.36%, with a 1.33% yield and 21.25% 5-year growth rate.
Why It Matters
The outperforming high-growth dividend stocks signal resilience and potential for future gains, making them attractive for income-focused investors amid broader market declines.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About RMD Stock
What is ResMed Inc.'s (RMD) stock forecast for 2025?
Based on our analysis of 21 Wall Street analysts, ResMed Inc. (RMD) has a median price target of $274.00. The highest price target is $295.00 and the lowest is $200.00.
Is RMD stock a good investment in 2025?
According to current analyst ratings, RMD has 12 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $245.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RMD stock?
Wall Street analysts predict RMD stock could reach $274.00 in the next 12 months. This represents a 11.5% increase from the current price of $245.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ResMed Inc.'s business model?
ResMed generates revenue by manufacturing and selling advanced medical devices for sleep apnea, COPD, and respiratory conditions. Their product line includes CPAP devices, bilevel systems, and ventilators, all designed to improve patient comfort. Additionally, the company leverages cloud-connected technology to offer monitoring and telemedicine services, enhancing patient engagement and compliance.
What is the highest forecasted price for RMD ResMed Inc.?
The highest price target for RMD is $295.00 from at , which represents a 20.0% increase from the current price of $245.78.
What is the lowest forecasted price for RMD ResMed Inc.?
The lowest price target for RMD is $200.00 from Craig Wong-Pan at RBC Capital, which represents a -18.6% decrease from the current price of $245.78.
What is the overall RMD consensus from analysts for ResMed Inc.?
The overall analyst consensus for RMD is bullish. Out of 21 Wall Street analysts, 12 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $274.00.
How accurate are RMD stock price projections?
Stock price projections, including those for ResMed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 5:00 PM UTC